RT Journal Article
SR Electronic
T1 Long-term Outcomes of Early-stage Non-stomach Gastrointestinal Mucosa-associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2851
OP 2857
DO 10.21873/anticanres.16454
VO 43
IS 6
A1 ITO, EIKO
A1 OGINO, ICHIRO
A1 SUGIURA, MADOKA
A1 WATANABE, SHIGENOBU
A1 TAYAMA, YOSHIBUMI
A1 TAKANO, SHOKO
A1 HATA, MASAHARU
YR 2023
UL http://ar.iiarjournals.org/content/43/6/2851.abstract
AB Background/Aim: Non-stomach gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma is rare, and there are only a few reports regarding radiation therapy (RT) for non-stomach gastrointestinal MALT lymphoma. There has been no established cure and no reports on RT use with long-term follow-up. Herein, we report a retrospective long-term investigation of early-stage non-stomach gastrointestinal MALT lymphoma. Our aim was to evaluate whether RT is a valid treatment option for this disease. Patients and Methods: We retrospectively analyzed 6 patients who were diagnosed with early-stage non-stomach gastrointestinal MALT lymphoma and received RT. The median age was 66 years (range=38-89 years). The primary tumor originated from the duodenum in 2 patients and from the rectum in 4 patients. The RT dose was 30-34 Gy in 15-20 fractions to the involved site or field, depending on the case. Results: The median follow-up time was 89.5 months (range=6-170). All patients had complete remission within 3 months after RT. The 5-year overall survival and progression-free survival rates were 83.3% and 100%, respectively. During the observation period, no patient had a confirmed recurrence. One patient died of causes unrelated to cancer or treatment. There were no late toxicities by RT. Conclusion: Our results show good long-term local control and no late toxicities requiring treatment. Moderate-dose RT was appropriate and well tolerated for early-stage non-stomach gastrointestinal MALT lymphoma.